ferroptosis plays a pivotal role in activating and modulating specific intracellular signaling pathways integrated into the therapeutic management of colorectal cancer

It is expected that the amount of recently diagnosed colon cancer cases will increase to around 3.2 million yearly until 2040. although early diagnostic procedures and management approaches have been improved, colorectal cancer (crc) treatment remains challenging. there is an urgent need to discover new therapeutic agents to enhance therapeutic strategies. ferroptosis is distinguished as a mode of regulated cell death considered by iron-dependent lipid peroxidation. contemporary investigations suggest that induction of ferroptosis in crc can effectively target neoplastic cells that are resistant to alternative forms of cell death. this review has summarized recent scientific work on the implications of ferroptosis in crc treatment and highlights its underlying molecular and biological mechanisms. while investigating its therapeutic potential, it shows the importance of diverse modulators of ferroptosis, including the 7-membered solute carrier family 11 or xct (slc7a11), reactive oxygen species (ros), glutathione (gsh), and iron in the context of crc. recent research has identified specific pathways and compounds that can induce ferroptosis in crc, such as apatinib and elesclimol, which are involved in pivotal signaling cascades. attenuation of proteins such as splicing factor, arginine/serine 9 (sfrs9), and tp53-induced glycolysis and apoptosis regulator (tigar) may increase the sensitivity of crc cells to ferroptosis, thus suggesting promising therapeutic avenues. compounds including imca and β-elemene have shown efficacy in inducing ferroptosis while minimizing toxicity to normal tissues, thereby demonstrating their potential as therapeutic agents for crc. participating ferroptosis stimulator drugs with current treatment regimens, such as cetuximab and aspirin, may offer better treatment outcomes for crc patients, especially those presenting resistance to conventional therapies.